Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer - PubMed (original) (raw)
doi: 10.1080/07357900500201301.
Michael P DiGiovanna, Zhao Lu, Chaya Moskowitz, Katherine S Panageas, Catherine Van Poznak, Clifford A Hudis, Larry Norton, Lee Tan, David F Stern, Darryl Carter, Andrew D Seidman
Affiliations
- PMID: 16203655
- DOI: 10.1080/07357900500201301
Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer
Shanu Modi et al. Cancer Invest. 2005.
Abstract
Purpose. To determine the association of phosphorylated/activated HER2 (P-HER2) and response to taxane chemotherapy in patients with metastatic breast cancer (MBC). Materials and Methods. Archived tumor specimens of patients with MBC treated on clinical trials with taxane monotherapy were analyzed by immunohistochemistry (IHC) for the presence of phosphorylated HER2 using the PN2A monoclonal antibody. Chi-squared analysis was performed to evaluate the association of P-HER2 status and efficacy of single agent taxane therapy. Results. One hundred twenty-six cases were identified as evaluable for both IHC and clinical outcome. Twelve cases (10 percent) were positive for P-HER2, of which 5 had evidence of clinical progression and 7 had evidence of clinical benefit with taxane therapy. Of the 114 cases that were negative for P-HER2, 20 demonstrated progression and 94 had clinical benefit. Chi-squared analysis revealed a significant correlation between the presence of P-HER2 and resistance to taxane therapy, chi2 = 3.9724 and p = 0.046. Conclusions. Phosphorylated/activated HER2 is associated with clinical resistance to single agent taxane therapy for MBC. The likelihood of direct progression of disease on taxane was greater in cases of PN2A-positive tumors (42 percent) as opposed to PN2A-negative ones (18 percent, p = 0.046). Functional assessment of HER2 status may provide unique predictive information not seen with conventional assessments.
Similar articles
- HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
Kim JW, Kim JH, Im SA, Kim YJ, Han HS, Kim JS, Lee KH, Kim TY, Han SW, Jeon YK, Oh DY, Kim TY, Park IA. Kim JW, et al. Cancer Chemother Pharmacol. 2013 Jul;72(1):109-15. doi: 10.1007/s00280-013-2174-1. Epub 2013 May 15. Cancer Chemother Pharmacol. 2013. PMID: 23673443 - Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer.
Van Poznak C, Tan L, Panageas KS, Arroyo CD, Hudis C, Norton L, Seidman AD. Van Poznak C, et al. J Clin Oncol. 2002 May 1;20(9):2319-26. doi: 10.1200/JCO.2002.08.125. J Clin Oncol. 2002. PMID: 11981003 - Safety and efficacy of first-line bevacizumab combined with taxane therapy in Chinese patients with HER2-negative locally recurrent or metastatic breast cancer: findings from the ATHENA study.
Xu BH, Jiang ZF, Shen ZZ, Guan ZZ, Chen ZD, Cheng Y, Zheng H, Jiang J, Wang XJ, Tong ZS, Qin SK, Luo Y, Yao M, Wang LW, He J. Xu BH, et al. Chin Med J (Engl). 2012 Mar;125(5):764-9. Chin Med J (Engl). 2012. PMID: 22490570 Clinical Trial. - Optimizing taxane use in MBC in the emerging era of targeted chemotherapy.
von Minckwitz G, Martin M, Wilson G, Alba E, Schmidt M, Biganzoli L, Awada A. von Minckwitz G, et al. Crit Rev Oncol Hematol. 2013 Mar;85(3):315-31. doi: 10.1016/j.critrevonc.2012.09.009. Epub 2012 Oct 30. Crit Rev Oncol Hematol. 2013. PMID: 23116625 Review. - Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies.
Murray S, Briasoulis E, Linardou H, Bafaloukos D, Papadimitriou C. Murray S, et al. Cancer Treat Rev. 2012 Nov;38(7):890-903. doi: 10.1016/j.ctrv.2012.02.011. Epub 2012 Mar 31. Cancer Treat Rev. 2012. PMID: 22465195 Review.
Cited by
- Modeling Neoadjuvant chemotherapy resistance in vitro increased NRP-1 and HER2 expression and converted MCF7 breast cancer subtype.
Al-Zeheimi N, Adham SA. Al-Zeheimi N, et al. Br J Pharmacol. 2020 May;177(9):2024-2041. doi: 10.1111/bph.14966. Epub 2020 Feb 15. Br J Pharmacol. 2020. PMID: 31883395 Free PMC article. - Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer.
Wu Y, Mohamed H, Chillar R, Ali I, Clayton S, Slamon D, Vadgama JV. Wu Y, et al. Breast Cancer Res. 2008;10(1):R3. doi: 10.1186/bcr1844. Epub 2008 Jan 10. Breast Cancer Res. 2008. PMID: 18184439 Free PMC article. - Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables.
Bai Y, Tolles J, Cheng H, Siddiqui S, Gopinath A, Pectasides E, Camp RL, Rimm DL, Molinaro AM. Bai Y, et al. Lab Invest. 2011 Aug;91(8):1253-61. doi: 10.1038/labinvest.2011.75. Epub 2011 Apr 25. Lab Invest. 2011. PMID: 21519325 Free PMC article. - Trastuzumab increases the sensitivity of HER2-amplified human gastric cancer cells to oxaliplatin and cisplatin by affecting the expression of telomere-associated proteins.
Liu Y, Ling Y, Qi Q, Zhu M, Wan M, Zhang Y, Zhang C. Liu Y, et al. Oncol Lett. 2015 Feb;9(2):999-1005. doi: 10.3892/ol.2014.2793. Epub 2014 Dec 12. Oncol Lett. 2015. PMID: 25624920 Free PMC article. - Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer.
Pinhel IF, Macneill FA, Hills MJ, Salter J, Detre S, A'hern R, Nerurkar A, Osin P, Smith IE, Dowsett M. Pinhel IF, et al. Breast Cancer Res. 2010;12(5):R76. doi: 10.1186/bcr2719. Epub 2010 Sep 28. Breast Cancer Res. 2010. PMID: 20920193 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous